Foscarnet salvage therapy for acyclovir-resistant varicella zoster: Report of a novel thymidine kinase mutation and review of the literature

Pediatric Infectious Disease Journal

Volumn 27, Issue 1, 2008, Pages 75-77

  Hatchette, Todd ^a   Tipples, Graham A ^b   Peters, Geoff ^b   Alsuwaidi, Ahmed ^c   Zhou, Jianwei ^b   Mailman, Timothy Lloyd ^c  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c IWK HEALTH CENTRE   (Canada)

Author keywords

Acyclovir resistance; Foscarnet; VZV

Indexed keywords

ACICLOVIR; FOSCARNET; THYMIDINE KINASE;

ARTICLE; CASE REPORT; CHEMOPROPHYLAXIS; DRUG MEGADOSE; FANCONI ANEMIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; PRIORITY JOURNAL; SCHOOL CHILD; VARICELLA ZOSTER VIRUS; VIRUS MUTATION;

EID: 37549062638     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181598315     Document Type: Article

References (35)

1. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361-381.
2. Clercq ED. Antiviral drugs in current clinical use. J Clin Virol. 2004;30:115-133.
3. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev. 2005;18:70-80.
4. Tipples GA, Safronetz D, Gray M. A real-time PCR assay for the detection of varicella-zoster virus DNA and differentiation of vaccine, wild-type and control strains. J Virol Meth. 2003;113:113-116.
5. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114-128.
6. Chilukuri S, Rosen T. Management of acyclovir resistant herpes simplex virus. Dermatol Clin. 2003;21:311-320.
7. Ida M, Kageyama S, Sato H, et al. Characterization of acyclovir susceptibility and genetic stability of varicella-zoster viruses isolated during acyclovir therapy. J Dermatol Sci. 2000;23:63-72.
8. Naesens L, De Clercq E. Recent developments in herpesvirus therapy. Herpes. 2001;8:12-16.
9. Reusser P, Cordonnier C, Einsele H, et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1996;17:813-817.
10. Bernhard P, Obel N. Chronic ulcerating acyclovir-resistant varicella zoster lesions in an AIDS patient. Scand J Infect Dis. 1995;27:623-625.
11. Biron KK, Fyfe JA, Noblin JE, Elion GB. Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus. Am J Med. 1982;73:383-386.
12. Boivin G, Edelman CK, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis. 1994;170:68-75.
13. Fillet AM, Dumont B, Caumes E, et al. Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization. J Med Virol. 1998;55:250-254.
14. Hoppenjans WB, Bibler MR, Orme RL, Solinger AM. Prolonged cutaneous herpes zoster in acquired immunodeficiency syndrome. Arch Dermatol. 1990;126:1048-1050.
15. Jacobson MA, Berger TG, Fikrig S, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;112:187-191.
16. Janier M, Hillion B, Baccard M, et al. Chronic varicella zoster infection in acquired immunodeficiency syndrome. J Am Acad Dermatol. 1998;18:584-585.
17. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2005;131:51-57.
18. Leibovitz E, Kaul A, Rigaud M, Bebenroth D, Krasinski K, Borkowsky W. Chronic varicella zoster in a child infected with human immunodeficiency virus: case report and review of the literature. Cutis. 1992;49:27-31.
19. Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis. 2003;188:954-959.
20. Linnemann CC Jr, Biron KK, Hoppenjans WG, Solinger AM. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS. 1990;4:577-579.
21. Lyall EG, Ogilvie MM, Smith NM, Burns S. Acyclovir resistant varicella zoster and HIV infection. Arch Dis Child. 1994;70:133-135.
22. Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother. 1999;43:2412-2416.
23. Breton G, Fillet AM, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis. 1998;27:1525-1527.
24. Pahwa S, Biron K, Lim W, et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA. 1988;260:2879-2882.
25. Safrin S, Berger TG, Gilson I, et al. Fosca therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991;115:19-21.
26. Saint-Leger E, Caumes E, Breton G, et al. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis. 2001;33:2061-2067.
27. Sawyer MH, Inchauspe G, Biron KK, Waters DJ, Straus SE, Ostrove JM. Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus. J Gen Virol. 1998;69(pt 10):2585-2593.
28. Snoeck R, Gerard M, Sadzot-Delvaux C, et al. Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient. J Med Virol. 1994;42:338-347.
29. Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes fro acyclovir-resistant mutants of varicella zoster virus isolated from patients with AIDS. J Virol. 1993;67:1024-1033.
30. Balfour HH Jr, Benson C, Braun J, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr. 1994;7:254-260.
31. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat. 2002;5:88-114.
32. Snoeck R, Andrei G, Clercq ED. Current pharmacological approaches to the therapy of varicella zoster virus infections. Drugs. 1999;57:187-206.
33. Snoeck R, Andrei G, Clercq ED. Novel agents for the therapy of varicella-zoster virus infections. Expert Opin Investig Drugs. 2000;9:1743-1751.
34. Visse B, Huraux JM, Fillet AM. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J Med Virol. 1999;59:84-90.
35. Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis. 2000;31:927-935.